A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients

Mette Calundann Noer; Cecilie Dyg Sperling; Sofie Leisby Antonsen; Bent Ottesen; Ib Jarle Christensen; Claus Høgdall

doi:10.1016/j.ygyno.2016.03.034

A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients

Mette Calundann Noer, Cecilie Dyg Sperling, Sofie Leisby Antonsen, Bent Ottesen, Ib Jarle Christensen, Claus Høgdall

14 Citationer (Scopus)

Abstract

OBJECTIVE: To develop and validate a new feasible comorbidity index based on self-reported information suited for preoperative risk assessment of ovarian cancer patients.

METHODS: The study was based on patient self-reported data from ovarian cancer patients registered in the Danish Gynecological Cancer Database between January 1, 2005 and December 31, 2012. The study population was divided into a development cohort (n=2020) and a validation cohort (n=1975). Age-stratified multivariate Cox regression analyses were conducted to identify comorbidities significantly impacting five-year overall survival in the development cohort, and regression coefficients were used to construct a new weighted comorbidity index. The index was applied to the validation cohort, and its predictive ability in regard to overall and cancer-specific five-year-survival was investigated. Finally, the performance of the new index was compared to that of the Charlson Comorbidity Index.

RESULTS: Regression coefficients of age and five comorbidities (atherosclerotic cardiac disease, chronic obstructive pulmonary disease, diabetes, dementia and hypertension) were included in the new comorbidity index. The validation study found the new index to be significantly associated to both overall survival (HR 1.44, p=0.013) and cancer-specific survival (HR 1.51, p=0.017) in multivariate analyses adjusted for other prognostic factors. The index was a significantly better predictor than the Charlson Comorbidity Index.

CONCLUSION: This new age-specific comorbidity index based on self-reported information is a significant predictor of overall and cancer-specific survival in ovarian cancer. It can be used to quickly identify those ovarian cancer patients requiring special attention in terms of preoperative optimization and postoperative care.

Originalsprog	Engelsk
Tidsskrift	Gynecologic Oncology
Vol/bind	141
Udgave nummer	3
Sider (fra-til)	471-8
Antal sider	8
ISSN	0090-8258
DOI	https://doi.org/10.1016/j.ygyno.2016.03.034
Status	Udgivet - jun. 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.ygyno.2016.03.034

Citationsformater

@article{bfe12bcb37684c98b7a277dc9ea8f29d,

title = "A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients",

abstract = "OBJECTIVE: To develop and validate a new feasible comorbidity index based on self-reported information suited for preoperative risk assessment of ovarian cancer patients.METHODS: The study was based on patient self-reported data from ovarian cancer patients registered in the Danish Gynecological Cancer Database between January 1, 2005 and December 31, 2012. The study population was divided into a development cohort (n=2020) and a validation cohort (n=1975). Age-stratified multivariate Cox regression analyses were conducted to identify comorbidities significantly impacting five-year overall survival in the development cohort, and regression coefficients were used to construct a new weighted comorbidity index. The index was applied to the validation cohort, and its predictive ability in regard to overall and cancer-specific five-year-survival was investigated. Finally, the performance of the new index was compared to that of the Charlson Comorbidity Index.RESULTS: Regression coefficients of age and five comorbidities (atherosclerotic cardiac disease, chronic obstructive pulmonary disease, diabetes, dementia and hypertension) were included in the new comorbidity index. The validation study found the new index to be significantly associated to both overall survival (HR 1.44, p=0.013) and cancer-specific survival (HR 1.51, p=0.017) in multivariate analyses adjusted for other prognostic factors. The index was a significantly better predictor than the Charlson Comorbidity Index.CONCLUSION: This new age-specific comorbidity index based on self-reported information is a significant predictor of overall and cancer-specific survival in ovarian cancer. It can be used to quickly identify those ovarian cancer patients requiring special attention in terms of preoperative optimization and postoperative care.",

keywords = "Journal Article",

author = "Noer, {Mette Calundann} and Sperling, {Cecilie Dyg} and Antonsen, {Sofie Leisby} and Bent Ottesen and Christensen, {Ib Jarle} and Claus H{\o}gdall",

year = "2016",

month = jun,

doi = "10.1016/j.ygyno.2016.03.034",

language = "English",

volume = "141",

pages = "471--8",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press",

number = "3",

}

TY - JOUR

T1 - A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients

AU - Noer, Mette Calundann

AU - Sperling, Cecilie Dyg

AU - Antonsen, Sofie Leisby

AU - Ottesen, Bent

AU - Christensen, Ib Jarle

AU - Høgdall, Claus

PY - 2016/6

Y1 - 2016/6

N2 - OBJECTIVE: To develop and validate a new feasible comorbidity index based on self-reported information suited for preoperative risk assessment of ovarian cancer patients.METHODS: The study was based on patient self-reported data from ovarian cancer patients registered in the Danish Gynecological Cancer Database between January 1, 2005 and December 31, 2012. The study population was divided into a development cohort (n=2020) and a validation cohort (n=1975). Age-stratified multivariate Cox regression analyses were conducted to identify comorbidities significantly impacting five-year overall survival in the development cohort, and regression coefficients were used to construct a new weighted comorbidity index. The index was applied to the validation cohort, and its predictive ability in regard to overall and cancer-specific five-year-survival was investigated. Finally, the performance of the new index was compared to that of the Charlson Comorbidity Index.RESULTS: Regression coefficients of age and five comorbidities (atherosclerotic cardiac disease, chronic obstructive pulmonary disease, diabetes, dementia and hypertension) were included in the new comorbidity index. The validation study found the new index to be significantly associated to both overall survival (HR 1.44, p=0.013) and cancer-specific survival (HR 1.51, p=0.017) in multivariate analyses adjusted for other prognostic factors. The index was a significantly better predictor than the Charlson Comorbidity Index.CONCLUSION: This new age-specific comorbidity index based on self-reported information is a significant predictor of overall and cancer-specific survival in ovarian cancer. It can be used to quickly identify those ovarian cancer patients requiring special attention in terms of preoperative optimization and postoperative care.

AB - OBJECTIVE: To develop and validate a new feasible comorbidity index based on self-reported information suited for preoperative risk assessment of ovarian cancer patients.METHODS: The study was based on patient self-reported data from ovarian cancer patients registered in the Danish Gynecological Cancer Database between January 1, 2005 and December 31, 2012. The study population was divided into a development cohort (n=2020) and a validation cohort (n=1975). Age-stratified multivariate Cox regression analyses were conducted to identify comorbidities significantly impacting five-year overall survival in the development cohort, and regression coefficients were used to construct a new weighted comorbidity index. The index was applied to the validation cohort, and its predictive ability in regard to overall and cancer-specific five-year-survival was investigated. Finally, the performance of the new index was compared to that of the Charlson Comorbidity Index.RESULTS: Regression coefficients of age and five comorbidities (atherosclerotic cardiac disease, chronic obstructive pulmonary disease, diabetes, dementia and hypertension) were included in the new comorbidity index. The validation study found the new index to be significantly associated to both overall survival (HR 1.44, p=0.013) and cancer-specific survival (HR 1.51, p=0.017) in multivariate analyses adjusted for other prognostic factors. The index was a significantly better predictor than the Charlson Comorbidity Index.CONCLUSION: This new age-specific comorbidity index based on self-reported information is a significant predictor of overall and cancer-specific survival in ovarian cancer. It can be used to quickly identify those ovarian cancer patients requiring special attention in terms of preoperative optimization and postoperative care.

KW - Journal Article

U2 - 10.1016/j.ygyno.2016.03.034

DO - 10.1016/j.ygyno.2016.03.034

M3 - Journal article

C2 - 27056103

SN - 0090-8258

VL - 141

SP - 471

EP - 478

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -

A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater